Company intelligence / Profile preview
YD Bio
Taipei, Taiwan
- Ownership
- Private
- Development stage
- Other
01
Overview
YD Bio has commercialized DNA methylation-based pancreatic cancer screening as a laboratory-developed test (LDT), with breast cancer recurrence monitoring LDT due in 2025; preclinical and early clinical programs in exosome- and stem cell-based ocular therapies with clinical trials planned for 2027. No pivotal readouts published yet; revenue primarily from product distribution and early-stage service offerings.
- Therapeutic areas
- OncologyOphthalmology
- Modalities
- DNA methylation-based diagnosticExosome-based therapyStem cell therapySmall moleculeBiologicMedical device
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
EG BioMed (exclusive cancer diagnostic licensing)3D Global Biotech (ocular stem cell/exosome therapies)
Beyond the preview
Go deeper on YD Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on YD Bio.